Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021054 | 0.87 | — | — | |
| SCHEMBL12021016 | 0.78 | — | — | |
| SCHEMBL7872706 | 0.77 | POLB (0.41) | KDM4EPOLBMEN1KMT2A | |
| SCHEMBL2656076 | 0.70 | ALDH1A1 (0.41) | POLBMEN1KMT2AMAPT | |
| SCHEMBL28786616 | 0.69 | POLB (0.36) | POLBMEN1KMT2A | |
| SCHEMBL5363394 | 0.60 | TSHR (0.52) | KDM4EPOLBMEN1KMT2A | |
| SCHEMBL2656358 | 0.60 | SMN1; SMN2 (0.42) | KDM4EPOLBMAPT | |
| SCHEMBL6829825 | 0.59 | TDP1 (0.49) | POLBMEN1KMT2A | |
| SCHEMBL5411234 | 0.58 | TSHR (0.40) | POLBMEN1KMT2A | |
| SCHEMBL7088668 | 0.58 | CA12 (0.41) | KDM4EPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-9522926-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-04-30 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940927-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2185570-B1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | KDM4E 4072/4885POLB 3914/4885MEN1 2932/4885 |
| US-20150119365-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | KDM4E 3996/4885POLB 3914/4885MEN1 3209/4885 |
| US-20110294758-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | KDM4E 3996/4885POLB 3914/4885MEN1 3209/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | KDM4E 3996/4885POLB 3914/4885MEN1 3209/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | KDM4E 4021/4885POLB 3756/4885MEN1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.